AcelRx Pharmaceuticals, Inc. (ACRX)の価格はいくらですか

AcelRx Pharmaceuticals, Inc. (ACRX)の価格は$0.922です

AcelRx Pharmaceuticals, Inc. (ACRX)の時価総額は何ですか

AcelRx Pharmaceuticals, Inc. (ACRX)の時価総額は$11.68Mです

AcelRx Pharmaceuticals, Inc. (ACRX) の利益

AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily dedicated to advancing and bringing to market medical solutions for managing acute pain. The company's key commercial products include DSUVIA and DZUVEO, which are 30 microgram sufentanil tablets administered under the tongue, intended for treating significant short-term pain. AcelRx also develops ZALVISO, a pre-programmed, patient-managed analgesia system that enables hospital patients experiencing moderate-to-severe acute pain to self-administer sufentanil sublingual tablets for their pain relief. In its development pipeline, AcelRx is progressing ARX-02, which is currently in Phase 2 clinical trials, targeting sudden, intense cancer-related pain in individuals who are tolerant to opioid medications. Another candidate, 4ARX-03, is being investigated for its utility in providing mild sedation and pain relief during various medical procedures that might cause discomfort. Beyond acute pain, AcelRx's investigational portfolio features Niyad, a regional anticoagulant designed for use in external blood circulation systems. Furthermore, LTX-608, a nafamostat formulation for direct intravenous infusion, is being explored as an experimental treatment for a range of conditions, including COVID, severe lung injury (acute respiratory distress syndrome), widespread blood clotting (disseminated intravascular coagulation), and acute pancreatitis. The company was founded in 2005 and initially operated under the name SuRx, Inc., before officially rebranding as AcelRx Pharmaceuticals, Inc. in August 2006. It is headquartered in Hayward, California.

年	利益	変化
提供された日付のデータは十分ではありません。

年

利益

変化

提供された日付のデータは十分ではありません。

企業	利益	利益の差	国
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$1.76B	-	IN

企業

利益

利益の差

国